Demis Hassabis in 2026: How DeepMind Is Turning AlphaFold Into a Drug Discovery Engine

Demis Hassabis, CEO of Google DeepMind and 2024 Nobel laureate in Chemistry, has spent the first months of 2026 articulating a specific and measurable thesis: AlphaFold, the protein-structure model that now serves more than three million researchers across 190 countries, is the first rung in an AI-powered scientific revolution, not the last. His clearest statement of this position came in a Semafor interview published 21 January 2026, where he described the commercial boom in generative AI as potentially slowing, not accelerating, progress toward deeper scientific breakthroughs.

The Paradox at the Heart of AI Progress

In his January 2026 Semafor interview, Hassabis offered an assessment that sits at odds with the prevailing industry narrative. "The paradox of AI progress," he said, is that the commercial success of generative AI may actually stretch out the timeline to whatever comes after it. Shortages in high-bandwidth memory and reduced open research sharing have created friction in scaling, which he acknowledged as potentially useful: "It may be a good thing that it's not as fast. There's a whole bunch of other things that we need to think through with this technology." He noted that commercial pressure has made it harder to share research openly, describing it as "a shame on the one hand, but understandable."

That framing is deliberate. Where competitors have staked out exponential-scaling positions, Hassabis is positioning DeepMind's approach around multimodal training data and reasoning rather than raw compute volume. "Text alone would not get you to the endgame faster," he told Semafor, explaining DeepMind's bet that reasoning would emerge through richer, multi-modal inputs. The implication is that DeepMind's path diverges from the brute-force scaling playbook, relying instead on architecture choices and domain-specific training.

In a separate Fortune interview in February 2026, Hassabis described his longer-term ambition as building toward "radical abundance," a state in which AI has bottled the scientific method and can autonomously run the hypothesis-experiment-publication cycle. "In 10, 15 years' time, we'll be in a kind of new golden era of discovery that is a kind of new renaissance," he told Fortune editor-in-chief Alyson Shontell.

AlphaFold to Isomorphic: From Protein Maps to Drug Candidates

Hassabis has consistently described AlphaFold as the opening chapter rather than the conclusion. The tool, which predicted the 3D structure of approximately 200 million proteins and made those predictions freely available, has been used by more than three million researchers in 190 countries since its public release, according to the Nobel Committee's October 2024 press release. That dataset forms the computational substrate for Isomorphic Labs, the DeepMind spinout Hassabis co-runs, which is now applying AlphaFold 3 to design entirely new small molecules and biologics targeting proteins previously considered undruggable.

The commercial architecture of that project became clearer in early 2024, when Isomorphic signed deals with Eli Lilly and Novartis together worth nearly $3 billion in potential milestone payments: $1.745 billion from Lilly (including $45 million upfront) and $1.237 billion from Novartis (including $37.5 million upfront), according to Fierce Biotech. The Novartis partnership was subsequently expanded in February 2025 to add three additional research programs.

The timeline for first-in-human trials has shifted. Hassabis indicated at Davos in January 2026 that clinical trials would begin by end-2026, a revision from an earlier target of end-2025, according to Yahoo Finance reporting citing MarketScreener. Isomorphic currently has 17 active drug development programs across oncology, immunology, and cardiovascular disease, with several lead candidates in the IND-enabling phase.

Where DeepMind Fits Inside Google's AI Structure

Hassabis runs Google DeepMind as a consolidated entity following the 2023 merger of DeepMind and Google Brain. Within Alphabet, the unit sits alongside Google's product teams but operates with a research-first mandate. His January 2026 Semafor interview touched on the tension between that mandate and the commercial reality of running under a public company: open research is becoming harder to sustain as competitive pressure intensifies across the industry.

His public statements in early 2026 also addressed China's AI development. In a CNBC interview on 16 January 2026, Hassabis said China's leading AI models were "months" behind US capability rather than years, a more compressed gap than many Western analysts had assumed. The comment came weeks after DeepSeek's R1 model drew significant attention for its cost efficiency.

The Nobel Prize, awarded October 2024 jointly with John Jumper and David Baker, has given Hassabis a platform that extends beyond the technology industry. In his Nobel lecture in Stockholm in December 2024, he described AlphaFold as "the first proof point of AI's incredible potential to accelerate scientific discovery," a framing he has repeated in every major interview since.

What It Means

Hassabis's public positioning in early 2026 reflects an institution that has already won the most prestigious scientific prize available and is now focused on converting that credibility into a drug discovery pipeline. Whether Isomorphic's first human trials arrive by end-2026 as projected, or slip further, will be the first concrete test of whether the AlphaFold thesis translates from structural biology benchmark to clinical asset. His argument is not that AI will imminently produce AGI, but that it will first produce measurable scientific outputs, starting with proteins, then drugs, then, in his framing, an entire new era of discovery. The metrics that matter in the next 12 months are IND filings and Phase 1 enrolments, not benchmark scores.

Sources

• Semafor: Google DeepMind's Demis Hassabis and the paradox of AI progress (Jan 21, 2026)
• Fortune: Google's Nobel-winning AI leader sees a 'renaissance' ahead (Feb 11, 2026)
• CNBC: China just 'months' behind US AI models, Google DeepMind CEO says (Jan 16, 2026)
• Nobel Prize: Nobel Prize in Chemistry 2024 press release
• Nobel Prize: Demis Hassabis Nobel lecture (Dec 8, 2024)
• Fierce Biotech: Alphabet's Isomorphic stacks two new deals with Lilly, Novartis worth nearly $3B (Jan 2024)
• Yahoo Finance / MarketScreener: Google-backed Isomorphic Labs delays clinical trial timeline (2026)
• Isomorphic Labs: Partnerships page
• Google DeepMind blog: Demis Hassabis and John Jumper awarded Nobel Prize in Chemistry

Editorial standards: every claim is sourced. Tips: [email protected]